Skip to main content

Table 2 Standardized AUCs for clinical, serological, comorbidity and treatment serial measurements of persistent and nonpersistent patients

From: Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability

AUC for serial assessments

Persistent-patients (n = 32)

Nonpersistent patients (n = 43)

P value

Clinical

   

   Disease activity score (28 joints)

2.83 ± 1.45

3.04 ± 0.89

0.45

   66 swollen joint counts

3.65 ± 5.06

3.99 ± 2.86

0.72

   68 tender joint counts

4.02 ± 5.16

3.94 ± 2.74

0.94

   Physician global assessment of disease activity visual analogue scale

11.72 ± 16.46

12.24 ± 7.60

0.87

   Patient pain visual analogue scale

11.79 ± 11.42

12.77 ± 7.24

0.65

   Patient overall disease visual analogue scale

11.73 ± 12.3

13.19 ± 7.26

0.52

   Health assessment questionnaire

0.23 ± 0.36

0.36 ± 0.32

0.23

Serological

   

   Erythrocyte sedimentation rate

16.99 ± 11.97

15.99 ± 9.67

0.69

   C-reactive protein

1.18 ± 1.52

0.73 ± 0.69

0.13

   Number of comorbidities/patient

1.33 ± 2.4

1.1 ± 1.48

0.62

Treatment

   

   Number of DMARDs/patient

2.31 ± 0.71

2.47 ± 0.71

0.35

   Number of drugs for comorbidity/patient

1.81 ± 1.03

1.83 ± 0.88

0.90

   Number of total drugs/patient

4.38 ± 1.13

4.61 ± 1.17

0.39

  1. Data presented as the mean ± standard deviation. AUC, area under the curve; DMARD, disease-modifying antirheumatic drug.